Pfizer Inc. and German partner BioNTech SE said Thursday a Phase 2/3 trial of their COVID-19 vaccine booster showed a high immune response in children aged 5-to-11-years old. Data from a sub-analysis of 30 sera from the trial showed a 36-fold increase in neutralizing titers against the omicron variant, which has become dominant globally. “These data demonstrate an increase in SARS-CoV-2 Omicron variant and wild-type strain neutralizing titers following a booster dose of the Pfizer-BioNTech COVID-19 vaccine compared to two doses,” the companies said in a joint statement. They are planning to submit the data to the Food and Drug Administration and other regulatory bodies in the coming days.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
